Misuse of Fentanyl and Heroin on the Rise During COVID-19 Pandemic

    The misuse of fentanyl, heroin and nonprescribed opioids is increasing, potentially due to the COVID-19 pandemic, according to a new study.

    Researchers from the Quest Diagnostics Health Trends study say the rise in drug misuse may be due to the pandemic’s impact on health care access and support for people most at risk for substance use disorder.

    The researchers analyzed more than 872,000 nationwide lab results. Their study is believed to be the largest to examine drug positivity rates before and during the first several months of the pandemic, according to a company news release.

    The study found among individuals tested, the drug positivity rate rose 35% for nonprescribed fentanyl and 44% for heroin during the pandemic compared to the period before the pandemic. Nonprescribed opioids rose 10%.

    “The COVID-19 pandemic has created the perfect storm for a rise in substance use disorders and other forms of prescription and illicit drug misuse. Stress, job losses and depression compounded with isolation and a lack of access to health services can trigger prescription medication overuse, illicit drug use, or relapses,” said co-author Harvey W. Kaufman, M.D., Senior Medical Director, Head of Health Trends Research Program, Quest Diagnostics.

    mother comforting son - family

    COVID-19: We Are Here for You

    In this uncertain time, we know that you may be concerned about keeping your families and your communities safe and healthy. We are dedicated to ensuring you have the support you need to address substance use and addiction — from prevention to recovery.

    Find help
    By Partnership Staff
    October 2020

    Published

    October 2020

    CONNECT WITH US

    Sign up to join our community working to end addiction.

    Please leave this field empty

    By entering your email address above you are opting in to receive email communications from Partnership to End Addiction and agreeing to our Terms of Use and Privacy Policy.

    No, thanks. Take me to the website.